Imatinib 100mg Tablet

The Imatinib 100mg Tablet is an oral targeted anticancer medicine that belongs to the tyrosine kinase inhibitor (TKI) class. It is commonly prescribed for the treatment of chronic myeloid leukemia (CML), Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL), and gastrointestinal stromal tumors (GIST). This tablet is an important component of modern targeted cancer therapy.

Imatinib works by selectively blocking abnormal tyrosine kinase proteins that promote uncontrolled cancer cell growth. Inhibiting these specific signalling pathways, it helps slow disease progression and control tumor development. The targeted mechanism allows for effective management of certain cancers when used as part of a structured treatment regimen.

Imatinib 100 mg Tablet is a prescription-only oncology medicine and must be taken strictly under the supervision of a qualified oncologist. The product is intended for oral administration and should be used according to prescribed dosage guidelines. Regular medical monitoring is required during treatment to ensure appropriate response and safety.

Product Features

• Oral tyrosine kinase inhibitor (TKI)
• Contains Imatinib 100 mg
• Used in leukemia and GIST treatment
• Targets BCR-ABL, KIT, and PDGFR pathways
• Once or multiple daily doses (as prescribed)
• Proven long-term clinical effectiveness
• Manufactured under GMP-compliant standards
• Prescription-required oncology medicine

How It Helps

• Blocks abnormal tyrosine kinase activity to control cancer cell growth
• Helps slow disease progression in CML, Ph+ ALL, and GIST
• Targets BCR-ABL, KIT, and PDGFR signalling pathways
• Supports long-term oral cancer therapy under an oncologist’s supervision